Mark your calendars: We will be showcasing our Leptomeningeal Metastases programs at the 2024 SNO Annual Meeting in Houston, Texas!
Plus Therapeutics will present data from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and discuss plans for continued clinical development as well as present results of the FORSEE Trial of circulating tumors cells for improved diagnosis and disease monitoring of LM.
In addition, we will host an educational symposium featuring clinical experts discussing LM and Plus’ recent announcements for our LM therapeutic and diagnostic programs.
Press Release: https://ir.plustherapeutics.com/press-releases
Recent Comments